120 related articles for article (PubMed ID: 38105142)
1. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38105142
[TBL] [Abstract][Full Text] [Related]
2. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA; Pham A; Jotte R; Hong DS; Garon EB; Traynor A; Olson P; Latven L; Yan X; Shazer R; Leal TA
J Thorac Oncol; 2023 Jul; 18(7):907-921. PubMed ID: 36842467
[TBL] [Abstract][Full Text] [Related]
3. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H; de Marinis F; Dumoulin D; Reynolds C; Theelen WSME; Percent I; Gutierrez Calderon V; Johnson ML; Madroszyk-Flandin A; Garon EB; He K; Planchard D; Reck M; Popat S; Herbst RS; Leal TA; Shazer RL; Yan X; Harrigan R; Peters S;
Ann Oncol; 2024 Jan; 35(1):66-76. PubMed ID: 37866811
[TBL] [Abstract][Full Text] [Related]
4. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
5. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
[TBL] [Abstract][Full Text] [Related]
6. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599023
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA; Msaouel P; Haymaker CL; Matin SF; Campbell MT; Zurita AJ; Shah AY; Wistuba II; Marmonti E; Duose DY; Parra ER; Soto LMS; Laberiano-Fernandez C; Lozano M; Abraham A; Hallin M; Chin CD; Olson P; Der-Torossian H; Yan X; Tannir NM; Wood CG
Nat Commun; 2023 May; 14(1):2684. PubMed ID: 37164948
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Girardi DM; Niglio SA; Mortazavi A; Nadal R; Lara P; Pal SK; Saraiya B; Cordes L; Ley L; Ortiz OS; Cadena J; Diaz C; Bagheri H; Redd B; Steinberg SM; Costello R; Chan KS; Lee MJ; Lee S; Yu Y; Gurram S; Chalfin HJ; Valera V; Figg WD; Merino M; Toubaji A; Streicher H; Wright JJ; Sharon E; Parnes HL; Ning YM; Bottaro DP; Cao L; Trepel JB; Apolo AB
Clin Cancer Res; 2022 Apr; 28(7):1353-1362. PubMed ID: 35031545
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Bauer T; Cho BC; Heist R; Bazhenova L; Werner T; Goel S; Kim DW; Adkins D; Carvajal RD; Alva A; Eaton K; Wang J; Liu Y; Yan X; Christensen J; Neuteboom S; Chao R; Pant S
Invest New Drugs; 2022 Oct; 40(5):990-1000. PubMed ID: 35767205
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
13. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.
Ohyama C; Kojima T; Kondo T; Naya Y; Inoue T; Tomita Y; Eto M; Hisasue S; Uemura H; Obara W; Kikuchi E; Sharma P; Galsky MD; Siefker-Radtke A; Grossfeld G; Collette S; Gooden K; Kimura G
Int J Clin Oncol; 2019 Sep; 24(9):1089-1098. PubMed ID: 31218529
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P; Siefker-Radtke A; de Braud F; Basso U; Calvo E; Bono P; Morse MA; Ascierto PA; Lopez-Martin J; Brossart P; Rohrberg K; Mellado B; Fischer BS; Meadows-Shropshire S; Abdel Saci ; Callahan MK; Rosenberg J
J Clin Oncol; 2019 Jul; 37(19):1608-1616. PubMed ID: 31100038
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT; Jaeger D; Chan E; Harbison C; Lin CS; Tschaika M; Azrilevich A; Rosenberg JE
Lancet Oncol; 2016 Nov; 17(11):1590-1598. PubMed ID: 27733243
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
[TBL] [Abstract][Full Text] [Related]
19. Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Qu YY; Sun Z; Han W; Zou Q; Xing N; Luo H; Zhang X; He C; Bian XJ; Cai J; Chen C; Wang Q; Ye DW
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35537782
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]